Skip to main content
Industry News
FDA grants priority review for zanubrutinib for MZL

The FDA has granted priority review status to Chinese pharma company BeiGene for its application for Brukinsa, or zanubrutinib, a treatment for pretreated marginal zone lymphoma. The submission is supported by data from the company's midstage MAGNOLIA trial.

Full Story: